Physician profile
Luz Rincon
NPI 1366719817
$1,569.20
in general payments reported to CMS, 2019-2025
20 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $158 · 2021: $155 · 2022: $372 · 2023: $267 · 2024: $42.83 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $256.81 | 2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $236.27 | 2020-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $218.68 | 2019-2022 | |
| Novo Nordisk INC | $198.88 | 2022-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $104.19 | 2020-2024 | |
| Pfizer INC. | $86.63 | 2019-2021 | |
| Stryker Corporation | $71.09 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Dexcom, INC. | $64.80 | 2022-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $53.27 | 2019-2020 | |
| Astellas Pharma US INC | $46.94 | 2019 | |
| Gilead Sciences, INC. | $43.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.70 | 2022 | |
| Allergan, INC. | $25.05 | 2020 | |
| Chiesi USA, INC. | $19.39 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.56 | 2025 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $16.92 | 2023 | Evkeeza |
| Abbvie INC. | $16.10 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.83 | 2019 | |
| Merck Sharp & Dohme LLC | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Rincon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.